KaydedilenlerDerginizi ekleyin

Dergiler / Türkderm Türk deri hastalıkları ve frengi arşivi / 2022 / Cilt: 56 - Sayı: 1

Methotrexate

Metotreksat

Nilgün ŞENTÜRK
Sayfa
17–20
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Its use in combination with phototherapy and acitretin has been found considerably effective.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Methotrexate is a drug used in the treatment of psoriasis and psoriatic arthritis.
📊
Temel Bulgular & Veri:When used as a monotherapy, methotrexate shows its effect late and achieves a 50-75% recovery in skin lesions.
💡
Sonuç & Katkı:Its use in combination with phototherapy and acitretin has been found considerably effective.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Methotrexate is a drug used in the treatment of psoriasis and psoriatic arthritis. It shows its effect by binding to dihydrofolate reductase, reducing purine synthesis and cell proliferation. When used as a monotherapy, methotrexate shows its effect late and achieves a 50-75% recovery in skin lesions. Patients using methotrexate should periodically be monitored for toxicity with relevant laboratory parameters. Its use in combination with folic acid reduces the risk of toxicity. Using it in combination with cyclosporine in low doses may lower the toxicity risk of both. Its use in combination with phototherapy and acitretin has been found considerably effective.

Abstract

Metotreksat psoriasis ve psoriatik artrit tedavisinde kullanılan etkisini dihidrofolat redüktaza bağlanarak purin sentezini ve hücre proliferasyonu azaltarak gösteren bir ilaçtır. Metotreksat tedavide monoterapi olarak kullanıldığında etkisi geç başlar. Monoterapi olarak kullanıldığında deri lezyonlarında %50-75 oranında iyileşme sağlar. Metotreksat kullanan hastalar toksisite açısından belirli periyotlarda ilgili laboratuvar parametreleri ile izlenmelidir. Folik asitle birlikte kullanılması toksisite riskini azaltır. Siklosporin ile birlikte düşük dozlarda kullanılması her iki ilacın da toksisite riskini azaltabilir. İlacın fototerapi ve asitretin ile birlikte kullanımının oldukça etkili olduğu bulunmuştur.

🔖

Bu Makaleye Atıf Yap

ŞENTÜRK, N. (2022). Methotrexate. Türkderm Türk deri hastalıkları ve frengi arşivi, Cilt: 56 - Sayı: 1, 17–20. https://ajindex.com/articles/418789

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Nast A, Amelunxen L, Augustin M, et al.: S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. J Dtsch Dermatol Ges 2018;16:645-69
  2. Menter A, Korman NJ, Elmets CA, et al.: Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4.Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85
  3. Cronstein B: How does methotrexate suppress inflammation? Clin Exp Rheumatol 2010;28(Suppl61):S21-3
  4. Friedman B, Cronstein B: Methotrexate Mechanism in Treatment of Rheumatoid Arthritis Joint Bone Spine 2019;86:301-7
  5. Meephansan J, Ruchusatsawat K, Sindhupak W, Thorner PS, Wongpiyabovorn J: Effect of methotrexate on serum levels of IL-22 in patients with psoriasis. Eur J Dermatol 2011;21:501-4
  6. Baran W, Batycka-Baran A, Zychowska M, Bieniek A, Szepietowski JC: Folate supplementation reduces the side effects of methotrexate therapy forpsoriasis. Expert Opin Drug Saf 2014;13:1015-21
  7. Bath RK, Brar NK, Forouhar FA, Wu GY: A review of methotrexate-associated hepatotoxicity. J Dig Dis 2014;15:517-24
  8. Rademaker M, Gupta M, Andrews M, et al.: The Australasian Psoriasis Collaboration View on Methotrexate for Psoriasis in the Australasian Setting Australas J Dermatol 2017;58:166-70
  9. NICE. Psoriasis: assessment and management of psoriasis. NICE guidelines [CG153]. London: Royal College of Physicians (UK) CTI - National Institute for Health and Clinical Excellence: Guidance; 2012 [updated 20141024]. Available from:
  10. Weinstein GD, Frost P: Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971;103:33-8
  11. Nyfors A, Brodthagen H: Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica 1970;140:345-55
  12. Flytström I, Stenberg B, Svensson A, Bergbrant IM: Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008;158:116-21
  13. Nast A, Sporbeck B, Rosumeck S, et al.: Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Invest Dermatol 2013;133:1963-70
  14. Aydin F, Canturk T, Senturk N, Turanli AY: Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol 2006;31:520-4
  15. Clark CM, Kirby B, Mor